|
BP13798
|
DCPLA-ME
|
|
|
|
|
DCPLA-ME is the methyl ester form of DCPLA and can be used to treat neurodegenerative diseases. It is an effective PKCε activator.
|
|
BP13797
|
DCP-LA
|
|
|
|
|
DCP-LA (FR236924), linoleic acid derivatives, selective and direct activation of PKCε.
|
|
BP13796
|
DCLX069
|
|
|
|
|
DCLX069 is a selective protein arginine methyltransferase 1 (PRMT1) inhibitor with an IC50 value of 17.9 µM. DCLX069 occupies the SAM binding pocket to exert the inhibitory effect. DCLX069 effectively blocks cell proliferation in breast cancer, liver cancer, and acute myeloid leukemia cell lines.
|
|
BP13795
|
DCH36_06
|
|
|
|
|
DCH36_06 as a bona fide is a potent p300/CBP inhibitor
|
|
BP13794
|
dCBP-1
|
|
|
|
|
dCBP-1 is a chemical degrader of p300/CBP. dCBP-1 hijacks the E3 ubiquitin ligase CRBN for selective degradation of p300/CBP. Degradation of p300/CBP by dCBP-1 leads to effective multiple myeloma cell killing.
|
|
BP13793
|
DC-05
|
|
|
|
|
DC-05 is an inhibitor of DNA methyltransferase 1 (DNMT1) (IC50 and a Kd: 10.3 μM and 1.09 μM, respectively).
|
|
BP13792
|
DC_517
|
|
|
|
|
DC_517 is an inhibitor of DNA methyltransferase 1 (DNMT1) ( IC50: 1.7 μM; Kd: 0.91 μM).
|
|
BP13791
|
Dbet57
|
|
|
|
|
dBET57 is heterobifunctional degrader of BRD4 based on the PROTAC technology, exhibits significant degradation of BRD4BD1 with a DC50/5h of 500 nM,and inactive on BRD4BD2
|
|
BP13790
|
dBET1
|
|
|
|
|
dBET1 is a hybrid molecule that combines (+)-JQ1 and thalidomide. It induces cereblon-dependent BET protein degradation in vitro (EC50: 430 nM) and induces apoptosis.
|
|
BP13789
|
Daminozide
|
|
|
|
|
Daminozide is a plant growth regulator, selectively inhibits the KDM2/7 JmjC subfamily.
|
|
BP13788
|
Cyproheptadine hydrochloride sesquihydrate
|
|
|
|
|
Cyproheptadine hydrochloride sesquihydrate, an antihistamine, is an antagonist of serotonin and histamine2.
|
|
BP13787
|
Cycloheterophyllin
|
|
|
|
|
Cycloheterophyllin has an antioxidant effect, it is a photoprotective agent that inhibits ultraviolet A (UVA)-induced oxidative stress and damage, and could be used in the research on and prevention of skin photoaging.
|
|
BP13786
|
CXD101
|
|
|
|
|
CXD101 is a novel class I-selective HDACi (HDAC1 (IC50 : 63nM), HDAC2 (IC50 :570nM), HDAC3 (IC50 :550nM)). CXD101 has no activity against HDAC class II
|
|
BP13785
|
CX-6258
|
|
|
|
|
CX-6258 is an orally valid Pim 1/2/3 kinase(IC50=5 nM/25 nM/16 nM) inhibitor. It has good biological activity and kinase specificity.
|
|
BP13784
|
CX-6258 hydrochloride
|
|
|
|
|
CX-6258 HCl is an effective, orally efficacious Pim1/2/3 kinase inhibitor (IC50: 5/25/16 nM).
|
|
BP13783
|
CTPB
|
|
|
|
|
CTPB is a p300 histone acetyltransferase (HAT) enzyme activator.
|
|
BP13782
|
CTB
|
|
|
|
|
CTB (Cholera Toxin B subunit) is an activator of p300 histone acetyltransferase and induces apoptosis in MCF-7 cells.
|
|
BP13781
|
CRT0066854 hydrochloride
|
|
|
|
|
CRT0066854 hydrochloride is an effective selective atypical PKCs inhibitor. CRT0066854 is against full-length (FL) PKCι, PKCζ, and ROCK-II kinases with IC50 values of 132 nM, 639 nM, and 620 nM, respectively.
|
|
BP13780
|
CRA-026440
|
|
|
|
|
CRA-026440 is a potent, broad-spectrum HDAC inhibitor (Kis: 4, 14, 11, 15, 7, and 20 nM for HDAC1, HDAC2, HDAC3, HDAC6, HDAC8, and HDAC10).
|
|
BP13779
|
CPUY074020
|
|
|
|
|
CPUY074020 is a potent and orally bioavailable inhibitor of histone methyltransferase G9a (IC50: 2.18 μM) with anti-proliferative activity.
|
